Comparing hypertrophy of the future liver remnant for two different strategies of portal vein embolization in patients with bilobar colorectal liver metastases – a retrospective European multicentre study
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Portal vein embolization (PVE) is a well-established technique for inducing liver hypertrophy in the future liver remnant (FLR) before major hepatectomy. A frequently used method in bilobar disease is the two-stage hepatectomy (TSH) technique combined with PVE (TSH-PVE). A novel approach is PVE, followed by a one-stage hepatectomy (OSH), combining major hepatectomy with clearing of the FLR (PVE-OSH). This study aimed to compare FLR hypertrophy between these two strategies for induced liver hypertrophy. MATERIAL/METHODS: Patients with bilobar colorectal liver metastases (CRLM) who underwent PVE from January 2013 to December 2021 were included in this retrospective, multicenter study. Aspects of hypertrophy of the FLR were compared between the groups. RESULTS: The study included 188 patients, 127 in the PVE-OSH group and 61 in the TSH-PVE group. There were no statistically significant differences between the two groups regarding FLR hypertrophy measured by absolute and relative growth, degree of hypertrophy or kinetic growth rate. No major complications were reported. DISCUSSION/CONCLUSION: No differences in FLR hypertrophy were demonstrated between the two different treatment strategies of TSH-PVE or PVE-OSH. This supports PVE-OSH as a feasible treatment option that reduces the surgical burden for patients with advanced, bilobar CRLM disease.
Source: HPB
Authors: Dennis Björk, Tim Reese, Anne M. Holmen Longva, Kristian S. Kiim, Maximilian Evers, Peter N. Larsen, Nicolai Aagaard Schultz, Bård I. Røsok, Ulrik Carling, Fredrik Holmquist, Gert Lindell, Per Sandström, Jörg Böcker, Stefan Gilg, Jennie Engstrand, Christian Sturesson, Karl J. Oldhafer, Ernesto Sparrelid, Bergthor Björnsson
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,100
OpenAlex ID: W4416971940
